← Back to Screener
Eledon Pharmaceuticals, Inc. Common Stock (ELDN)
Price$3.49
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)105.67%
Price vs S&P 500 (4W)-11.56%
VGM Score65.32
Market Capitalization$272.47M
All Metrics
Book Value / Share (Quarterly)$1.32
P/TBV (Annual)1.09x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.91
Price vs S&P 500 (YTD)122.39%
EPS (TTM)$-0.83
10-Day Avg Trading Volume0.91M
EPS Excl Extra (TTM)$-0.83
EPS (Annual)$-0.56
ROI (Annual)-33.35%
Cash / Share (Quarterly)$1.46
ROA (Last FY)-26.99%
EBITD / Share (TTM)$-0.95
ROE (5Y Avg)-65.84%
Cash Flow / Share (Annual)$-0.83
P/B Ratio2.71x
P/B Ratio (Quarterly)2.33x
Net Income / Employee (Annual)$-1,382,300
ROA (TTM)-52.94%
EV / EBITDA (TTM)19.24x
EPS Incl Extra (Annual)$-0.56
Current Ratio (Annual)7.40x
Quick Ratio (Quarterly)8.30x
3-Month Avg Trading Volume1.23M
52-Week Price Return15.36%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.90
52-Week High$4.60
EPS Excl Extra (Annual)$-0.56
Tangible BV CAGR (5Y)-7.98%
26-Week Price Return119.25%
Quick Ratio (Annual)7.30x
13-Week Price Return32.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.44x
Enterprise Value$266.32M
Book Value / Share Growth (5Y)-32.07%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.77
3-Month Return Std Dev68.68%
Net Income / Employee (TTM)$-2,368,100
ROE (Last FY)-33.35%
EPS Basic Excl Extra (Annual)$-0.56
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.83
ROI (TTM)-71.97%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.38
Price vs S&P 500 (52W)-12.79%
Year-to-Date Return133.77%
5-Day Price Return-9.49%
EPS Normalized (Annual)$-0.56
ROA (5Y Avg)-58.65%
Month-to-Date Return-7.35%
Cash Flow / Share (TTM)$-2.83
EBITD / Share (Annual)$-1.02
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-65.84%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.83
P/TBV (Quarterly)3.43x
P/B Ratio (Annual)0.83x
Book Value / Share (Annual)$1.81
Price vs S&P 500 (13W)22.04%
Beta1.03x
Revenue / Share (TTM)$0.00
ROE (TTM)-71.97%
52-Week Low$1.35
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.33est. -0.19
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.23
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ELDNEledon Pharmaceuticals, Inc. Common Stock | — | — | B | $3.49 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Eledon Pharmaceuticals is a clinical-stage biotech company developing tegoprubart, an anti-CD40L antibody targeting a well-validated pathway with broad therapeutic potential. The company is pursuing applications across transplantation, autoimmune diseases, and ALS, addressing significant unmet medical needs in each indication.